Señales en vivo de POLB.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:29):

Stats
Volumen de hoy	5.01M
Volumen promedio	2.05M
Capitalización de mercado	66.75M
EPS	£0 ( 2024-04-30 )
Próxima fecha de ganancias	( £0 ) 2024-05-10
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-13.35
ATR14	£0.0940 (0.70%)

Volumen Correlación

Largo: -0.19 (neutral)

Corto: 0.09 (neutral)

Signal:(41.85) Neutral

Poolbeg Pharma PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Poolbeg Pharma PLC Correlación - Moneda/Commodity

0.07
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.02
( neutral )

0.37
( neutral )

0.08
( neutral )

Poolbeg Pharma PLC Finanzas

Annual	2023
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.00790

FY	2023
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.00790

FY	2022
Ingresos:	£0
Beneficio Bruto:	£-26 000.00 (0.00 %)
EPS:	£-0.00940

Financial Reports:

No articles found.

Poolbeg Pharma PLC

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.